While Epogen and Neupogen addresses anemia and neutropenia, no therapy has existed for the treatment of lymphopenia until ANKTIVA® –The Cancer BioShield. Landmark overall survival benefit (P-value ...

ImmunityBio, Inc.’s Anktiva shows promise for bladder cancer, but faces FDA setbacks and a rocky approval path. Peak sales for Anktiva’s indications could reach $900 million by 2028, implying a 73% ...

Burkitt lymphoma is a highly aggressive B-cell non-Hodgkin lymphoma whose diagnosis relies on integrated clinical, pathological, and imaging assessments. Established diagnostic criteria include ...

Over the past decade, there has been a significant increase in the number of approved drugs for treating lymphoma. Before the ...